ClinicalTrials.gg
CompletedNCT00772681Tax-NazoUpdated Dec 7, 2009

Efficacy of Chemoradiotherapy After Neoadjuvant Cisplatin and Docetaxel in the Nasopharynx Carcinoma

A Phase 4 interventional study of docetaxel and cisplatin in Head and Neck Neoplasms, sponsored by Sanofi. Completed at 1 site in Turkey. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2009-12-07.

Sponsored by Sanofi · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
57
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 68 studies testing docetaxel in Head and Neck Neoplasms — 3 open to participants now, 6 under way, none of them phase 3. Docetaxel · Head and Neck Neoplasms.

Enrollment
15th of 64
57 · median 34
Started
2004
with 4 others
Phase 4
2 of 68
none open now
Registered
41st of 68
by date
Lead sponsor
6 of 68
Sanofi

Among the 68 studies testing docetaxel in Head and Neck Neoplasms, this one is the 15th largest by enrollment of the 64 interventional ones that give a count, is one of 5 that started in 2004, is one of 2 in phase 4, and was the 41st registered.

Head and Neck Neoplasms

2,713 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

3 of the 68 studies testing docetaxel in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies testing docetaxel in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

  • To assess the efficacy of docetaxel, cisplatin combination in terms of disease free survival.
  • Time to progression of the disease in terms of local and distant failure; assess the survival time, and assess the objective (clinical and radiological) response rate and the safety of the treatment.
03

Conditions studied

  • Head and Neck Neoplasms
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Histologically/ confirmed, patients with stage T2b-T4N1 or TanyN2-3 undifferentiated or nonkeratinized squamous cell carcinoma of nasopharynx who are candidate for curative radiotherapy.
  • Performance Status is 0-1
  • Weight loss within last 6 months \<10% of body weight
  • Acceptable haematological profile (as defined by a leukocyte count ≥ 4000/mm3, a count ≥ 100.000mm3 and ≥ 9g/100mL), and adequate renal function (as defined by serum creatinine ≤ 1.5mg/dl), and hepatic function (as defined by ≤ 1.5 x maximum normal value even with hepatic ; transaminases (, AST) ≤ 1.5 x maximum normal value; alkaline phosphatase ≤ 2.5 x maximum normal value, except in case of a bone metastasis)

Exclusion criteria

Exclusion Criteria:

  • Patients with stage IVC or disease
  • Patients treated with chemotherapy for nasopharyngeal cancer
  • Patients treated with radiotherapy to head and neck region
  • Concomitant use of another anti-cancer therapy
  • Patients treated with amifostine or pilocarpine during protocol treatment.
  • Unstable medical condition that makes the patient unable to take part in a clinical study (congestive heart failure, serious arrhythmia, uncontrolled diabetes mellitus), history of myocardial infarction within last 6 months, massive pleural, peritoneal or pericardial effusion; or presence of serious uncontrolled infection.
  • Presence of other tumours different from carcinoma of the skin except melanoma and carcinoma in situ of the breast and cervix with disease free survival less than 5 years.
  • Pregnancy or breastfeeding. In women of and in men, an adequate method must be used
  • Social or psychological condition that render the patient inadequate for the follow-up of the study
  • for any of the study drugs (e.g. history of to any of the ingredients of the study drugs)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    1

    Drug: docetaxel and cisplatin

Interventions

  • Drugdocetaxel and cisplatin

    Drug pages: Docetaxel · Cisplatin

    3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks

06

What researchers measure

Primary outcomes

  1. Complete response rate after neoadjuvant chemotherapy

    Time frame: From the start date of the treatment to the date of first documented progression of disease or at least until 2 years follow-up period

Secondary outcomes

  1. Percentage of patients whose is disease controlled locally or regionally

    Time frame: from the start date of the treatment to the date of first documented local or regional tumor progression

  2. Median length of overall survival

    Time frame: time interval from the date of treatment to the date of death or at least until 2 years follow-up period

  3. Median length of disease free survival

    Time frame: time interval from the date of treatment to the date of death or at least until 2 years follow-up period

  4. Percentage of alive patients without metastatis

    Time frame: from the start date of the treatment to the date of first documented distant metastasis

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Istanbul, Turkey
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2004, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2008
First posted
Oct 15, 2008
Start
Oct 2004
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Last update
Dec 7, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 7, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00772681
Lead sponsor
Sanofi
First posted
Oct 15, 2008
Start date
Oct 2004
Primary completion
Mar 2008
Completion
Mar 2008
Last update
Dec 7, 2009

Study contacts

Edibe Taylan, MD
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Docetaxel · Cisplatin

Start the discussion